Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | The Balancing Act® Talks Novel Treatment for Infantile Hemangioma; Technology for Work and PlayPierre Fabre Pharmaceuticals, Inc., iRULU® with Host Julie Moran Take Center Stage on April 29
By: o2 media 
BA_logo NEW O2 Media Pamela@o2mediainc.com (954) 691-1102 The Balancing Act® Talks Novel Treatment for Infantile Hemangioma; Technology for Work and Play Pierre Fabre Pharmaceuticals, Inc., iRULU® with Host Julie Moran Take Center Stage on April 29 (POMPANO BEACH, Fla. – PR LOG – April 24, 2015) Award-winning morning show The Balancing Act® will feature a novel treatment for infantile hemangioma, a benign vascular tumor, also known as a “Strawberry Mark”, and introduce the hottest technology for work and play on the show airing on Wednesday, April 29, 2015 at 7:30 a.m. (ET/PT) on Lifetime®. Tune in as The Balancing Act hosts help jump start the day with lively conversations, and trusted information to empower a woman’s life. The encore presentation of this episode will air on Wednesday, May 6, 2015. Don’t miss these featured segments taking center stage on The Balancing Act: - Technology for Work and Play – with iRULU® Busy women trying to balance it all are looking for technology that they can operate in multiple capacities, that is high quality yet low priced. The Balancing Act welcomes back Elizabeth Little, Director of Marketing for iRULU®, to profile the companies’ 2-in-1 laptop/tablet, designed with a women’s needs in mind. The stylish hybrid has the power and usability of a laptop, and the portability of a tablet, helping make women’s lives easier and more productive. For more information, please visit: www.iRULU.com - Novel treatment, for Infantile Hemangioma, commonly called a “Strawberry Mark” - with Pierre Fabre Pharmaceuticals, Inc. A prominent bright red patch on a baby’s skin, commonly called a “Strawberry Mark”, is a skin condition named Infantile Hemangioma, a common vascular benign growth that affects numerous newborn babies. Mainly occurring on the baby’s face, scalp and neck, some can be dangerous to a child’s health, or leave permanent tissue damage if untreated. Until recently, previous treatments carried significant side effects. Join Dr. Ana Duarte, Founder of the Children’s Skin Center and Head of Dermatology at Miami Children’s and a couple and their baby who had the condition as they discuss the first FDA approved treatment that has changed the landscape of Pediatric Dermatology. For more information, please visit: www.hemangeol.com. For more information from patient support groups, please visit the Vascular Birthmark Foundations at www.birthmark.org and the National Organization of Vascular Anomalies at www.novanews.org/ Joe Bonaccorso, Vice President of Pierre Fabre Pharmaceuticals stated, “Pierre Fabre Pharmaceuticals is happy to support Health Care Providers and Caregivers with this breakthrough treatment.” Dr. Linda Roselle Shannon PhD, President and Founder of the Vascular Birthmark Foundation said “Hemangeol has changed the lives of the families affected by hemangiomas for the better. This drug has given hope where no hope has previously existed.” Karla Hall, Executive Director, National Organization of Vascular Anomalies stated, “Hemangeol has changed the way children with infantile hemangioma are treated, for the better. It allows patients to have access to treatment earlier, with fewer side effects and with better results than we have seen with other treatment options.” IMPORTANT SAFETY INFORMATION Do not give HEMANGEOL® (propranolol hydrochloride) - was born prematurely and has not reached the corrected age of 5 weeks - weighs less than 4 ½ pounds - is allergic to propranolol or any of the other ingredients in HEMANGEOL - has asthma or a history of breathing problems - has a heart problem, slow heart rate (less than 80 heart beats per minute), very low blood pressure - is at risk for low blood sugar, for example is vomiting or unable to take feedings - has high blood pressure caused by a tumor on the adrenal gland, called “pheochromocytoma” Tell the doctor about all medicines your child is taking, or all the medicines you are taking if you are breastfeeding. HEMANGEOL can cause serious side effects, including: Low blood sugar (hypoglycemia) If your child has any of the signs or symptoms of low blood sugar listed below during treatment with HEMANGEOL, stop giving your child HEMANGEOL and call your doctor or go to the nearest emergency room right away. Signs or symptoms of low blood sugar include: pale, blue or purple skin color, sweating, irritability, crying for no apparent reason, irregular or fast heartbeat, poor feeding, low body temperature, unusual sleepiness, seizures, breathing stops for short periods of time, and loss of consciousness HEMANGEOL can cause serious side effects, including: - Slow heart rate (bradycardia) - Breathing problems or wheezing - Stroke in certain severe problems with the blood vessels in their brain, particularly if your child has a large hemangioma that affects the face or head. Call your doctor or go to the nearest hospital emergency room if your child has: - pale skin color, slow or uneve n heartbeats, arms or legs feel cold, blue or purple skin color, or fainting. - breathing problems or wheezing during treatment The most common side effects include: sleep problems, worsening respiratory tract infections, diarrhea, and vomiting. These are not all the possible side effects of HEMANGEOL. Talk your doctor for medical advice about side effects. HEMANGEOLis a prescription medicine used to treat proliferating infantile hemangioma that requires treatment with a medicine that spreads throughout the body. For more information about HEMANGEOL, talk to your doctor or visit www.hemangeol.com About The Balancing Act® Entering its 7th season, The Balancing Act continues to empower women in all aspects of their lives. The mission at The Balancing Act is simple - to help today’s modern woman balance it all by bringing them positive solutions to enrich and empower them. Entertaining, educational and trusted by women, viewers can tune in to America’s premier morning show The Balancing Act on weekday mornings Monday through Friday at 7:30 am (ET/PT) on Lifetime. For additional information or to view a segment visit: http://www.thebalancingact.com/ For more information regarding O2 Media and TV Brand Integration go to: http://o2mediainc.com/ Join the Conversation! Like us on Facebook at: https://www.facebook.com/ Follow us on Twitter at: http://twitter.com/ Watch us on YouTube at: http://www.youtube.com/ End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number